Intellia Therapeutics, Inc. has grown revenue 3.9% a year over three years and 7.3% a year over five. Revenue growth, 3-year annual rate: +3.9% (Biotechnology median +17%). Revenue growth, 5-year rate: +7.3%, growth has slowed since the five-year average. Years of annual history on file: 11, FY2015 to FY2025, as filed.

NTLAIntellia Therapeutics, Inc.

Healthcare

$13.08-16% 1Y

$13.08

$8.0452 weeks$27.98

Latest close: back above its 200-day averageOct 9, 2026what changed →

Is it growing?

Good

Growing: revenue growing +13% year on year and operating margin widening (+192.4 points).

2 good, 1 without data

Revenue trend+13% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +7% a year.

Margin direction+192.4 points operating

Trailing-twelve-month operating margin, -844.5% now against -1036.9% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NTLA growing?

Intellia Therapeutics, Inc. has grown revenue 3.9% a year over three years and 7.3% a year over five.

+3.9%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +7.3%
Revenue growth, 5-year rate · +3.9% over three · growth has slowed since the five-year average
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed

Details›